Emmaus Life Sciences, Inc. Share Price Other OTC
Equities
EMMA
US29137T1016
Biotechnology & Medical Research
Sales 2021 | 20.61M 1.72B | Sales 2022 | 18.39M 1.54B | Capitalization | 12.9M 1.08B |
---|---|---|---|---|---|
Net income 2021 | -15M -1.25B | Net income 2022 | -10M -835M | EV / Sales 2021 | 4.97 x |
Net Debt 2021 | 20.13M 1.68B | Net Debt 2022 | 28.8M 2.4B | EV / Sales 2022 | 2.27 x |
P/E ratio 2021 |
-5.16
x | P/E ratio 2022 |
-1.21
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.23% |
Managers | Title | Age | Since |
---|---|---|---|
George Sekulich
PSD | President | 59 | 01/19/01 |
Willis Lee
CHM | Chairman | 64 | 17/19/17 |
Yasushi Nagasaki
DFI | Director of Finance/CFO | 57 | 01/11/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Peu Zen
BRD | Director/Board Member | 71 | 17/19/17 |
Willis Lee
CHM | Chairman | 64 | 17/19/17 |
Ian Zwicker
BRD | Director/Board Member | 77 | 17/19/17 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |